MCM
RCKT icon

M28 Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

M28 Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$721K Hold
210,871
– – 1.53% 8
2026
Q1 		$755K Sell
210,871
-174,809
-45% -$695K 1.4% 7
2025
Q4 		$1.35M Hold
385,680
– – 0.98% 7
2025
Q3 		$1.26M Hold
385,680
– – 1.85% 7
2025
Q2 		$945K Hold
385,680
– – 1.61% 9
2025
Q1 		$2.57M Hold
385,680
– – 3.53% 5
2024
Q4 		$4.85M Hold
385,680
– – 4.76% 3
2024
Q3 		$7.12M Hold
385,680
– – 7.83% 3
2024
Q2 		$8.3M Hold
385,680
– – 10.76% 3
2024
Q1 		$10.4M Sell
385,680
-137,600
-26% -$3.91M 7.68% 4
2023
Q4 		$15.7M Hold
523,280
– – 12.99% 3
2023
Q3 		$10.7M Sell
523,280
-107,100
-17% -$1.95M 12.3% 3
2023
Q2 		$12.5M Sell
630,380
-91,700
-13% -$1.85M 16.55% 2
2023
Q1 		$12.4M Hold
722,080
– – 13.99% 2
2022
Q4 		$14.1M Buy
722,080
+56,200
+8% +$1.03M 13.47% 2
2022
Q3 		$10.6M Sell
665,880
-50,000
-7% -$780K 11.09% 3
2022
Q2 		$9.85M Hold
715,880
– – 11.04% 3
2022
Q1 		$11.4M Buy
715,880
+220,600
+45% +$3.81M 10.44% 3
2021
Q4 		$10.8M Buy
+495,280
New +$13.5M 8.44% 5

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

M28 Capital Management's RCKT Position: Q2 2026 in Review

M28 Capital Management held its Rocket Pharmaceuticals (RCKT) position steady in Q2 2026 at 210,871 shares worth $721K. The position accounts for 1.53% of the portfolio, ranked #8.

M28 Capital Management first reported a position in RCKT in Q4 2021 and has held it in 19 quarters since. The position peaked at $15.7M in Q4 2023. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • M28 Capital Management held 210,871 shares of Rocket Pharmaceuticals worth $721K as of Q2 2026.
  • M28 Capital Management left its Rocket Pharmaceuticals share count unchanged in Q2 2026.
  • Rocket Pharmaceuticals made up 1.53% of M28 Capital Management's portfolio in Q2 2026, its #8 holding.
  • M28 Capital Management first reported a position in Rocket Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • M28 Capital Management's Rocket Pharmaceuticals position peaked at $15.7M in Q4 2023.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on M28 Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.